This is one risk that has always concerned me. I've said for many years that PNV should be a long term blue chip Australian owned share. Novosorb applications are effectively endless and we are only now touching the surface of our first almost billion $ market... hence even now I'd vote against a buy out at below $2/share... the medical advantages Novosorb brings are nothing short of extraordinary... let's keep the IP locally owned... if we can...
...hoping for updates on breast reconstruction/hernia/diabetes cure/drug elucidating pellets... perhaps before the AGM??
Gav
Early knockout blow, page-7
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.34 |
Change
-0.070(2.90%) |
Mkt cap ! $1.616B | |||
| Open | High | Low | Value | Volume |
| $2.36 | $2.38 | $2.29 | $4.296M | 1.844M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 26821 | $2.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.35 | 4554 | 2 |
View Market Depth
| Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
| PNV (ASX) Chart |